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Background: Major depression will become the second most important cause of disability in 2020. Computerized
cognitive-behaviour therapy could be an efficacious and cost-effective option for its treatment. No studies on cost-
effectiveness of low intensity vs self-guided psychotherapy has been carried out. The aim of this study is to assess
the efficacy of low intensity vs self-guided psychotherapy for major depression in the Spanish health system.
Methods: The study is made up of 3 phases: 1.- Development of a computerized cognitive-behaviour therapy for
depression tailored to Spanish health system. 2.- Multicenter controlled, randomized study: A sample (N=450
patients) with mild/moderate depression recruited in primary care. They should have internet availability at home,
not receive any previous psychological treatment, and not suffer from any other severe somatic or psychological
disorder. They will be allocated to one of 3 treatments: a) Low intensity Internet-delivered psychotherapy +
improved treatment as usual (ITAU) by GP, b) Self-guided Internet-delivered psychotherapy + ITAU or c) ITAU.
Patients will be diagnosed with MINI psychiatric interview. Main outcome variable will be Beck Depression
Inventory. It will be also administered EuroQol 5D (quality of life) and Client Service Receipt Inventory (consume of
health and social services). Patients will be assessed at baseline, 3 and 12 months. An intention to treat and a per
protocol analysis will be performed.
Discussion: The comparisons between low intensity and self-guided are infrequent, and also a comparative
economic evaluation between them and compared with usual treatment in primary. The strength of the study is
that it is a multicenter, randomized, controlled trial of low intensity and self-guided Internet-delivered
psychotherapy for depression in primary care, being the treatment completely integrated in primary care setting.
Trial registration: Clinical Trials NCT01611818
Keywords: Depression, Computer-delivered psychotherapy, Randomized controlled trialBackground
Major depression is a prevalent mental disorder associated
with significant disability and economic costs [1]. In this
sense, it is known that 25% of all human beings will suffer
from a depression at any moment over their lives [2] and,
according to the World Health Organization [3], depres-
sion will become the second most important cause of* Correspondence: jgarcamp@arrakis.es
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distribution, and reproduction in any mediumdisability in 2020. From the perspective of the health sys-
tem, 25-35% of the patients attending primary care
settings suffer from a psychiatric disorder and more than
80% of them are depression and/or anxiety [4]. This per-
centage is higher at the Spanish Primary Care where 45%
of the patients have had a mental disorder during their
life, with 31% experiencing a mental disorder in the past
12 months [5]. Almost 30% attendees reported a lifetime
history of major depressive disorder, with 9.6% experien-
cing major depression in the past year. In most countries,
general practitioners refer only 5-10% of the patients withCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pite of that, mental health services are collapsed all over
the world.
Major depression can be treated effectively using
antidepressants, but relapse is high following cessation,
and many patients prefer psychological therapies [6],
which are as effective as pharmacological treatment [7].
Although evidence-based treatments exist, rates of treat-
ment seeking are low, and many patients with depres-
sion do not receive adequate management, being the
main barriers the limited availability of trained clinicians
with consequent long waiting lists, direct and indirect
costs of treatment, stigma, and difficulty attending ther-
apy during business hours [8]. These reasons, expected
to get worse in the future, had convinced international
health authorities to search for new cost-effective treat-
ment alternatives for depression [9].
It has been defined “Computer-delivered psychother-
apy” (CDP) as any psychotherapy program that uses
patients’ inputs to take decisions regarding treatment
[10-12]. This excludes videoconferences, self-help
programs exclusively based on bibliotherapy, chats, help
groups, etc. Patients receive therapy using their
computers at home and the sessions are usually short
(20–30 min.), on a weekly basis and the treatment lasts
3–6 months [10-12]. At this moment, there exist evi-
dence of the effectiveness of CDP in depression [13],
anxiety [14], and other psychiatric disorders such as al-
cohol abuse, psychosomatic disorders [15] or even pain
[16]. Recently, cost-effectiveness studies on CDP have
been published with satisfactory results [17-20]. The
results has lead to British NICE to support the use of a
computer-delivered psychotherapy program for the
treatment of depression ("Beating the Blues") to be
widely used by the patients of the British National
Health Service [11,21]. Other studies show that CDP is
so effective that it should be used not only at primary
care level, but even in mental health services. In these
specialized settings, it would be recommended as a self-
help first step for depression and anxiety, before being
attended by a psychologist or psychiatrist [22]. Recently,
other CDP programs without the presence of a psycho-
therapist, such as "Blues Begone", have been evaluated
with adequate effectiveness not only in randomized con-
trolled trials [23] but in naturalistic studies as well [24].
Internet-delivered psychotherapy (iPT) is a form of
CDP delivered by internet. According to NICE [21], iPT
programs are highly structured and comprises systemat-
ically presented online lessons, homework, and supple-
mentary resources. Programs may be entirely self-guided,
or patients may receive therapist contact via asynchronous
e-mails or synchronous online chat or telephone calls.
Depending on the time devoted by the psychotherapist to
the patient, iPT programs can be broadly divided intolow-intensity (<3 h) and high-intensity iPT (>3 h of ther-
apist time in total) [25]. Although an Internet connec-
tion and basic computer hardware are required, some
of the advantages of iPT include convenience, treat-
ment fidelity, and accessibility. That is, patients and
therapists may logon to the program at anytime, every
patient receives exactly the same materials, and barriers
relating to stigma, geography and limited therapist re-
sources are minimized [21].
While there is consensus about the effectiveness of
iPT for major depression, it is still unknown how these
interventions work and for whom they work. This holds
true for other types of intervention as well, despite some
exploratory studies on this subject [26,27]. For this rea-
son, it is relevant to examine potential mediating and
moderating variables that explain the effect of these
treatments. Another key challenge is how to successfully
adapt and disseminate iPT programs developed and
evaluated in a research environment to the heteroge-
neous health services of developed and developing coun-
tries. One recent example is a program that was effective
in reducing depressive symptoms in an RCT [28], but
which did not improve treatment outcomes when added
to treatment as usual in primary care settings [29].
Regarding this, it is recommendable to develop studies
in which iPT be integrated within usual primary care
services. The efficacy and reliability of iPT have been
demonstrated for depression in different countries and
different languages, especially English, but as far as we
know, there is no validated internet delivery program in
Spanish. Since Spanish is, after English one of the most
used languages in the world, it seems highly relevant
that an online treatment program in Spanish for
depressive patients in primary care could be tested. Fi-
nally, an unresearched question is the attitude towards
iPT not only of the patients that receive it, but of the
health professionals (both general practitioners and
psychologists/psychiatrists) and stakeholders. Curiously,
the attitudes of professionals are usually more negative
than patients’ [30,31], but both are moderated by their
experience with iPT [32,33]. To better tailor the
programs to the environment in which they are intended
to be used and about the acceptability to stakeholders,
in order to facilitate the integration of these programs
into the health system, qualitative studies to identify
attitudes and barriers are systematically recommended.
The main objective of this study will be to compare
the effectiveness of a low intensity vs. a self-guided
Internet-delivered psychotherapy program compared
with ITAU for the treatment of major depression in pri-
mary care in Spain, with a multicenter, randomized, con-
trolled trial. The secondary objective will be the cost-
effectiveness of those programs, to identify the patients
that most benefit of these programs and to examine the
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describe the design of the study.
Methods
Study design
This study is a multicenter, randomized controlled
trial. Subjects will be randomized into three groups:
a) Low intensity Internet-delivered psychotherapy, b)
Self-guided Internet-delivered psychotherapy and c)
improved Treatment as Usual (ITAU) group in pri-
mary care. The evaluation of the treatment outcomes
will be performed at patient level and they will be
assessed individually.
Setting and study sample
Patients will be recruited from primary health care
centers of the three Spanish regions participating in the
study. Patients will be recruited by general practitioners
(GPs) working in these primary care centers until the
required sample is completed, without a quota of
patients assigned for each centre. Patients considered for
inclusion are those aged 18–65 years, able to understand
and read Spanish, with moderate or mild major depres-
sion, duration of symptoms longer than 2 weeks, access
to Internet at home and having an email address. Exclu-
sion criteria includes any psychological treatment during
last year, severe psychiatric disorder in Axis I (alcohol/
substances abuse or dependence, psychotic disorders or
dementia) and patients with severe depression (indicated
by a Beck-II score of 29 or higher) who will be advised
to consult their GP. Receiving pharmacological treat-
ment with antidepressants is not an exclusion criteria
meanwhile, during the study period, treatment will not
be modified or increased (decrease of pharmacological
treatment is accepted). Diagnosis of major depression
will be carried out with MINI International Neuro-
psychiatric Interview + scoring of moderate or mild de-
pression using Beck Depression Inventory II. Cut-off
point for this questionnaire is: 0–13: minimal depres-
sion; 14–19: mild depression; 20–28: moderate depres-
sion; 29–63: severe depression [34,35].
Sample size
The sample size of this study was based on the expected
difference on the primary outcome variable, i.e. depres-
sive symptoms, between the intervention groups and the
Treatment as Usual group at post-test. Based on a power
of 0.80 in a one-tailed test, an alpha of 0.05, we need
100 subjects in each condition to show an effect-size of
0.40.
Therefore, the total sample size was determined at
300. This sample size also allows calculating clinically
significant difference in the main outcome variable, Beck
Depression Inventory II. Based on previous studies [36],this difference has been placed at 5 points. It allows
changing scoring from normality to mild depression or
from mild to moderate depression. Taking account an
expected withdrawal rate of 30% according to previous
studies [9-14], a sample size of 450 patients (150 by arm)
was calculated. The three participating health centers will
select 150 patients with cluster randomization to allocate
one third in each of the three arms.Recruitment
Participants will be recruited in primary care settings by
participating GPs among patients fulfilling study criteria.
When the GP identifies a potential participant, he will
explain the patient the characteristics of the study.
Whether the patient is interested in participating he/she
will sign an informed consent and the GP will fill a
document describing the sociodemographic and clinical
characteristics of the patient and will give him/her the
patients’ information sheet and a handout describing the
study. After giving informed consent, subjects will be
interviewed in the next 3 days by a researcher. After
confirming that have signed the informed consent and
understand the study and the treatment options, the re-
searcher will administer psychological tests related with
inclusion criteria: MINI International Neuropsychiatric
Interview and Beck Depression Inventory II. Patients in
the ITAU arm will be allowed to follow psychotherapy
program at the end of the study for ethical reasons.
Whether the patient fulfills all study criteria, the re-
searcher will administer the remaining baseline tests and
will contact an independent researcher to implement
randomization.
Recruitment will be done in a consecutive way up to
complete sample size and it is expected to take a period
of 12 months. Recruitment calculations have been
carried out, on conservative bases, according to PRE-
DICT data study [36] that describes a cumulated
incidence of depression of 11.5% of the consulting popu-
lation in primary care. That is to say that for every 1000
non-depressed consulting patients in primary care, 115
will get depressed over 1 year. Since the prevalence of
depression is 14%, a GP with a standard consultation
made up of 1500 patients, will have 210 patients
diagnosed of major depression. From the remaining
1290 non-depressed patients, 148 will get depressed over
1 year, which stands for 2.8 patients a week or 12.3
patients a month. Assuming that every GP will invite
25% of those 12 possible patients and that only 25% will
fulfill criteria to participate in the study and will give
consent to it, every GP will recruit 1 patient/month
during the estimated 12-month recruited period. This
allows an estimation of at least 10 GPs for every region
(Aragon, Balearic Islands and Andalucía).
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Each patient will be allocated to either one of the three
groups using a computer-generated random number se-
quence. We will use block allocation, with 3 blocks (one
for each participating region) including 150 patients per
block, with about 50 patients per arm. The allocation will
be carried out by an independent person, belonging to
REDIAPP (Primary Care Prevention and Health Promo-
tion Research Network), who is not involved in the study.
The method used to implement the random allocation se-
quence will be a central telephone. The sequence will be
concealed until interventions are assigned. Patients will
agree to participate before the random allocation and
without knowing which treatment they will be allocated
to. Study personnel conducting psychological assessments
will be masked to participants' treatment conditions.
The researcher that administers baseline assessments
will be unaware of the treatment group to which the pa-
tient belongs to. This researcher will be different from
the one that administer the questionnaires over the
study. GPs will be also unaware, as long as possible, of
the arm to which the patient has been randomized, since
their treatment should be exclusively based on the
recommendations of the guides for the treatment of de-
pression. The flowchart of the study is summarized in
Figure 1 (Insert by here).
Interventions
Internet-delivered psychotherapy
The program “Smiling is fun” is an internet-delivered,
multimedia, interactive, self-help program for the treat-
ment of depression, developed by our group based on
similar programs in other countries that have dem-
onstrated to be effective [37,38]. The treatment protocol
is composed of 8 therapeutic modules and two initial
modules (home and welcome). The therapeutic modules
are oriented to work on different psychological tech-
niques which will allow the individual to learn and prac-
tice adaptive ways to cope with depression and daily
problems. Each module includes exercises to practice
such techniques. These modules are sequential, in order
to move step by step, all along the program. Duration of
the program can vary among users, it is estimated that
duration for most people will be 3 months. The content
of the program is the following:
– M1. Motivation for change which aim is to analyze
the advantages and disadvantages of changing,
emphasizing the importance of being motivated,
promoting the individual’s implication to practice
and learn all the abilities the program introduces.
– M2. Understanding emotional problems: This
module provides information to recognize and
understand the emotional problems.– M3. Learning to move on: This module focuses on
behaviour activation by teaching the importance of
“moving on” to acquire a proper level of activity and
involvement in life.
– M4. Learning to be flexible: This module aims to
teach a more flexible way of thinking and to
interpret situations, in order to be able to seeing
every situation from different perspectives, learning
to think about different alternatives.
– M5. Learning to enjoy: This module is devoted to
teach the importance and performance of positive
experiences that generate positive emotions,
promoting the involvement in pleasant and
significant activities, and contact with other people.
– M6. Learning to live: This module involves a further
step in the enhancement of positive affect,
understanding the importance of identifying the
individual’s own psychological strengths and
selecting and carrying out meaningful activities
linked to values and goals in life.
– M7. Living and learning: This module focuses on
developing an action plan to boost the individual
psychological strengths.
– M8. From now on, what else. . .?: This final module
aims to go on and strengthen what has been learnt
during the program.
The program recommends working on one module at
least for one complete week. The program sends a re-
inforcing message when the user finishes each module
and when the user performs the homework. On the
other hand, the program sends an email to the user and
to the clinician when more than two weeks between
sessions have passed without using it. This message
encourages the patient to continue working to benefit of
the program.
Patients randomized to this treatment will be given a
password to accede to the program at home. An adher-
ence protocol using data from the program will be
implemented to know which sessions and homework the
patient has done, how much time has taken for every
session and psychotherapy technique and the break he
has taken in every session. The patients allocated to this
intervention will be broken down in two different
groups:
– Low intensity Internet-delivered psychotherapy. Over
the treatment period, a researcher trained in
psychotherapy will contact with the patients to offer
help (asking for any difficulties or problems to fulfil
the program), and suggesting to end the therapy
within the estimated period. The patient could ask
questions or advice to the psychotherapists with a
total maximum of <1 hour over the treatment
Patients recruited by GPs that 
probably fulfill inclusion criteria
Screening by researches using 
MINI interview (N=450)
Randomized allocation of 
participating patients
Intervention group 1:
ITAU + low intensity internet-
delivered psychotherapy N=150
Intervention group 2:
ITAU + self-guided internet 
delivered psychotherapy N=150
Control group:
Improved treatment as usual 
(ITAU) n=150
Recruited 
patients
Recruited 
patients
Recruited 
patients
Included  
patients
Included  
patients
Included  
patients
- Losses
- Ineligibility
- Losses
- Ineligibility
- Losses
- Ineligibility
Monitoring: baseline 
3 and 12 months
Monitoring: baseline 
3 and 12 months
Monitoring: baseline 
3 and 12 months
Figure 1 Flowchart of the study: randomization, sampling and monitoring of patients.
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problem with the running program in order to solve
technological problems.
– Self-guided Internet-delivered psychotherapy. In this
group there will not be any contact with any
therapist over the treatment period. Only technical
questions about the working of the program could
be asked to a technician by mail.
Both groups of patients will receive treatment as usual
improved by their GPs, as described in the next
paragraph.Improved Treatment as Usual at primary care level (ITAU)
All the patients included in the study (whether they re-
ceive psychotherapy or not) will be also treated by their
GPs. In practice, ITAU in primary care is any kind of
treatment administered by the GP to the patient with
depression. However, it can be considered that the
Treatment as Usual in primary care will be improved be-
cause the participating GP will receive a training pro-
gram of 3 hours on a widely used Spanish Guide for the
Treatment of Depression in Primary Care, which is
based on the NICE recommendations for this subject[39]. This Guide describes the use of antidepressants in
adequate doses and time of administration. In case of
suicide risk, severe social dysfunction or worsening of
symptoms, it is recommended to refer the patient to
mental health facilities [40].
For the three groups the use of health and social
services (health professionals, medications, social
workers and other services) will be registered using the
CSRI [41].Instruments
Patients will be assessed at baseline, posttreatment, and
3 and 12 months after inclusion. The study variables
assessed are summarized in Table 1.Main outcome
Severity of depressive symptomatology measured by
Beck Depression Inventory II [34] using its Spanish
validated version [35]. This is one of the most widely
instrument used to evaluate severity of depression in
pharmacological and psychotherapy trials. This ques-
tionnaire has been used because it is recommended to
assess depression in primary care patients in which
comorbidity with medical disorders is frequent.
Table 1 Study variables
Instrument Assessment area Time of assessment Applied by
MINI Neuropsychiatric interview [31,32] Psychiatric diagnosis Baseline Researcher A
Beck II Depression Inventory [40,41] Severity of depression Baseline and follow-up sessions* Researcher A (baseline)
Researcher B (follow-up sessions)
Sociodemographic data Gender, age, marital status, education,
occupation, economical level
Baseline Researcher A
SF-12 Health Survey [40,41] Baseline and follow-up sessions* Researcher A (baseline)
Researcher B (follow-up sessions)
EQ-5D [42] Health related quality of life Baseline and follow-up sessions* Researcher A (baseline)
Researcher B (follow-up sessions)
CRSI [43] Health and social services use Baseline and follow-up sessions* Researcher A (baseline)
Researcher B (follow-up sessions)
Follow-up sessions: Postreatment, 3 and 12 months postreatment.
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Socio-demographic variables. The following socio-
demographic data will be collected: gender, age, marital
status (single, married/relationship, separated/divorced,
and widowed), education (years of education), occupa-
tion, economical level (in relation with Spanish mini-
mum monthly salary that at the moment of the study
was 640€).
Mini-International Neuropsychiatric Interview (MINI).
This is a short structured diagnostic psychiatric inter-
view that yields key DSM-IV and ICD-10 diagnoses [42].
MINI can be administered in a short period of time and
clinical interviewers need only a brief training. The
MINI has been translated and validated in Spanish [43].
EuroQoL-5D questionnaire (EQ-5D – Spanish version)
[44]. Generic instrument of health-related quality of life.
It has two parts: Part 1 records self-reported problems
in each of five domains: mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression. Each
domain is divided into three levels of severity
corresponding to no problems, some problems, and ex-
treme problems, which allows obtaining a population-
based preference score or societal index (SI). A total of
243 theoretically possible health states can be obtained
and the SI is calculated on the basis of these health
states. Values range from 1 (best health state) to 0
(death). However, this index may also provide negative
values that correspond to health states perceived as
worse than death. Utility scores for these health states
were assigned using the readily available Spanish popula-
tion tariffs [45]. Part 2 records the subject's self-assessed
health on a VAS, a 10 cm vertical line on which the best
and worst imaginable health states score 100 and 0,
respectively.
Client Service Receipt Inventory – adapted (CSRI –
Spanish version) [41,46]. Questionnaire for collecting in-
formation about use of healthcare and social careservices and other economic impacts (such as time off
work due to illness). The variant used in this study was
designed to collect retrospective data on service
utilization during the previous months after the last as-
sessment. Data on baseline assess the previous three
months before inclusion.
Overall Depression Severity and Impairment Scale
[47]: OASIS consists of 5 items that measure the fre-
quency and severity of anxiety, as well as level of avoid-
ance, work/ school/home interference, and social
interference associated with anxiety. The instructions
orient the respondent to considerate wide range of anx-
iety symptoms (e.g., panic attacks, worries, flashbacks)
when answering the questions, and the time frame is
“over the past week”. Respondents select among five dif-
ferent response options for each item, which are coded
0–4 and summed to obtain a total score. A psychometric
analysis of the OASIS in an undergraduate sample
suggested that the scale was unidimensional and has ad-
equate psychometric properties [47].
Overall Depression Severity and Impairment Scale
[47]: ODSIS is a self-report measure consists of 5 items.
In this case, evaluating experiences related to depression.
ODSIS measure the frequency and severity of depres-
sion, as well as level of avoidance, work/ school/home
interference, and social interference associated with
depression. Respondents select among five different
response options for each item, which are coded 0–4
and summed to obtain a total score. This instrument
can also be used to assess severity and impairment
associated with low mood. ODSIS assesses the frequency
with which the person has been depressed, the intensity
of symptoms, behavioral avoidance and functional im-
pairment associated with depression. So far, there are
not published studies examining the psychometric prop-
erties of this scale. Norman et al. [47] recommended use
and interpret it the same way to the OASIS.
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[48] consists of 20 items that evaluate two independent
dimensions: positive affect (PA) and negative affect (NA).
The range for each scale (10 items on each) is 10 to 50.
The instrument’s psychometric properties are quite satis-
factory. It has a validated Spanish version [49].
Credibility/expectancy questionnaire [50]. This instru-
ment is a quick and easy-to-administer scale for
assessing treatment expectancy and rationale credibility.
Credibility has been defined as how believable, convin-
cing, and logical the treatment is, whereas expectancy
refers to improvements that clients believe will be
achieved [51]. This questionnaire derives the two
predicted factors (cognitively based credibility and rela-
tively more affectively based expectancy) that are stable
across different populations [52]. The aspects that
address these two scales relate to: 1) treatment rationale,
2) treatment satisfaction, 3) degree to which I would rec-
ommend to a friend who had the same problem, 4) ex-
tent to which is considered to be useful in the same
case, 6) extent to which the intervention would be
considered aversive. This scale has demonstrated ad-
equate psychometric properties [52]. Our research team
has used these scales repeatedly in previous studies with
good results [53].
Ethical aspects
Informed consent will be obtained from the participants
before they are aware of which group they are to be
included in. Before they give their consent, the patients
will be provided with a general overview of the aims and
characteristics of the study and the psychological and
pharmacological intervention. They will also be
informed that they will be participating voluntarily, and
that they can choose to withdraw at any time with the
guarantee that they will continue to receive the treat-
ment considered most appropriate by their GP. The
study follows Helsinki Convention norms and posterior
modifications and the Declaration of Madrid of the
World Psychiatric Association. For ethical reasons,
patients allocated to Treatment as Usual will be offered
the possibility to complete the psychotherapy program.
The Study Protocol was approved by the Ethical Review
Board of the regional health authority (ref: PI10/039).
Analysis strategy
Analysis of clinical efficacy
The analysis will be per intent to treat and will follow
CONSORT recommendations [54]. First, the three
groups will be compared in order to verify that there are
no significant differences among them at baseline to
confirm they are comparable after randomization.
For comparisons, the ANOVA for continuous variables
and the Chi-squared test for categorical variables will beused. Non-parametric tests may also be used. To con-
firm main hypothesis, an analysis of variance (ANOVA)
of repeated measures, including all the assessments over
the time, will be carried. The main outcome, scoring of
BDI-II, will be used as continuous variable. Models will
include adjustment by baseline value of BDI-II and any
other variable that show differences among groups at
baseline. Possible interactions Group × Time will be
assessed using Mixed Factorial Anova (3 × 4: 3 groups
by 4 temporal moments). Other linear regression models
will be used to compare differences in BDI-II scoring
among groups for each assessment over the time
compared to baseline. Similar analysis will be carried out
for secondary outcomes. For missing values a sensitivity
analysis will be used to estimate the effect of missing
values. Those valued will be replaced using different
systems such as last registered values and imputations.Descriptions of costing procedure
Costs will be estimated from the healthcare and societal
perspective during the one year of follow-up. Direct health
care costs will be calculated by adding the costs derived
from medication consumption (antidepressants and
anxyolitics), medical tests, use of health-related services,
and cost of staff to run the intervention. The cost of medi-
cation will be calculated by determining the price per
milligram during the study, according to the Vademecum
International (Red Book; edition 2013), including value-
added tax. Total costs of medications will be calculated by
multiplying the price per milligram by the daily dose in
milligrams and the number of days receiving such treat-
ment. The main source of unit cost data related to public
medical tests and use of health services will be provided
by the tariffs published in the Official Government Board
of each Autonomous Community participating in the
study. Tariffs for private sector will be obtained in each re-
gion consulting the last published tariff and inflated to
2013 using national Consumer Price Index. Indirect costs
will be calculated considering the days on sick leave and
multiplying them by the minimum daily wage in Spain for
2013. Finally, total costs will be calculated by adding direct
and indirect costs. The unit costs will be expressed in
Euros (€) based on prices in 2013.Utilities
These represent the rating of the patients’ quality of life
on a scale from 0 (as bad as death) to 1 (perfect health).
Negative values are possible indicating a health state that
is “worse than death”. Patients describe their quality of
life using the EQ-5D, which is preferred for economic
evaluations from a societal perspective. Quality Adjusted
Life Years (QALYs) are calculated using Spanish tariffs
of EQ-5D.
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Cost-utility is explored through the calculation of incre-
mental cost-utility ratios (ICUR), defined as the differ-
ence in mean costs divided by difference in mean
QALYs [55]. As the duration of the study is 12 months,
neither costs nor outcomes are subject to discounting.
QALYs gained in each evaluation are approximated by
using the area under-the-curve technique. To gain
insight into the uncertainty around the pooled mean
ICUR, we will plot the pooled bootstrapped cost-effect
pairs on cost-utility planes. Bootstrapping involves
resampling with replacement from the original sample a
sufficiently large number of times in order to approxi-
mate the distribution of the population from which the
original data are drawn [56]. In our analyses, 1,000
samples will be generated. This distribution is used to
calculate the probability that each of the treatments is
the optimal choice, subject to a range of possible max-
imum values (ceiling ratio) that a decision-maker might
be willing to pay for a unit improvement in outcome.
Cost-utility acceptability curves are presented by plotting
these probabilities for a range of possible values of the
ceiling ratio [57]. The acceptability curve represents the
probability that the intervention is cost-effective, given a
varying threshold for the willingness to pay for each
QALY gained. The curves obtained incorporate the uncer-
tainty that exists around the estimates of expected costs
and expected effects associated with the intervention [58].
We assume that data will be missing completely at
random. Only patients with both cost and relevant out-
come data at 12-month follow-up will be included in the
cost-utility analyses. Notwithstanding, the robustness of
the cost-utility results will be tested by also imputing
missing 12-month data (sensitivity analysis). The impu-
tations will be performed using the multiple imputation
procedure in STATA 11.0.Forecast execution dates
Initial recruitment of patients: September 2012
Finalization of patient recruitment: December 2013
Finalization of patient monitoring period: June 2014
Publication of results: December 2014Discussion
The effectiveness of Internet-delivered psychotherapy for
depression has been demonstrated [12,18]. However, the
comparisons between low intensity and self-guided are
infrequent, and also a comparative economic evaluation
between them and compared with usual treatment in
primary. The strength of the study is that, to our know-
ledge, this is the first multicenter, randomized, con-
trolled trial of low intensity and self-guided Internet-
delivered psychotherapy for depression in primary care,being the treatment completely integrated in primary
care setting.
A number of potential limitations may be difficulties
in recruitment, owing to negative attitudes of discon-
tinue pharmacological treatment and changes in employ-
ment status because many patients are either on sick
leave or applying for disability pensions, making it diffi-
cult to interpret the results.
Clinical implications
This is probably the first study in Spain aiming to im-
prove clinical status and quality of life of depressed
patients in the community using an internet cognitive
psychotherapy. If positive results are achieved, we can-
not avoid the high impact this intervention would bring
to the society. Moreover, if this therapy is efficient it
means that it would be suitable for implementation from
an economic point of view.
The treatment program proposed in this study includes
therapeutic strategies that have proven their efficacy for
depression, but it is also based on the rationale of
transdiagnostic approaches that are emerging in the psy-
chopathology and treatments fields. Such approaches are
focused on fundamental processes underlying different
disorders, helping to explain comorbidity among dis-
orders, and leading to more effective assessment and treat-
ment strategies. In the present study, the program targets
the treatment of moderate depression and adjustment
disorders. If the program efficacy is proven, then it could
be used in other problems where depression or adjust-
ment disorders are comorbid or common symptomatol-
ogy is present. It may also have advantages in ease of
dissemination and in treating other emotional disorders.
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